ASCO 2026: FDA-Cleared AI Put to the Test
Multimodal AI platform goes head-to-head with a standard breast cancer assay using routine pathology image
-
1
The study data presented at ASCO 2026 focuses on an FDA-cleared AI system for breast cancer diagnostics.
-
2
The AI system is designed to work in conjunction with standard breast cancer diagnostic tests.
-
3
Corey Speers is the Professor and Chair of Radiation Oncology at the University of Alabama at Birmingham.
-
4
The presentation highlights the effectiveness of the AI system in enhancing diagnostic accuracy.
-
5
The study aims to evaluate the performance of the AI system in clinical settings.
